Private Trust Company’s Supernus Pharmaceuticals SUPN Stock Holding History

Private Trust Company’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-94	Closed	-$4.49K	–	2664
2025 Q3	$4.49K	Sell	94 -34	-27%	-$1.37K	﹤0.01%	2179
2025 Q2	$4.04K	Sell	128 -35	-21%	-$1.12K	﹤0.01%	2129
2025 Q1	$5.34K	Buy	163 +35	+27%	+$1.24K	﹤0.01%	2005
2024 Q4	$4.63K	Hold	128	–	–	﹤0.01%	2003
2024 Q3	$3.99K	Hold	128	–	–	﹤0.01%	2019
2024 Q2	$3.42K	Hold	128	–	–	﹤0.01%	2052
2024 Q1	$4.37K	Hold	128	–	–	﹤0.01%	1966
2023 Q4	$3.7K	Sell	128 -160	-56%	-$4.24K	﹤0.01%	2018
2023 Q3	$7.94K	Hold	288	–	–	﹤0.01%	1682
2023 Q2	$8.66K	Hold	288	–	–	﹤0.01%	1676
2023 Q1	$10.4K	Hold	288	–	–	﹤0.01%	1566
2022 Q4	$10K	Sell	288 -55	-16%	-$1.91K	﹤0.01%	1563
2022 Q3	$12K	Hold	343	–	–	﹤0.01%	1391
2022 Q2	$10K	Buy	+343	New	+$9.82K	﹤0.01%	1516

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Trust Company's SUPN Position: Q4 2025 in Review

Private Trust Company sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 94 shares — an estimated $4.49K sold.

Private Trust Company first reported a position in SUPN in Q2 2022 and held it in 14 quarters. The position peaked at $12K in Q3 2022. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

Private Trust Company reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Private Trust Company sold 94 Supernus Pharmaceuticals shares in Q4 2025, an estimated $4.49K.
Private Trust Company first reported a position in Supernus Pharmaceuticals in Q2 2022 and held it in 14 quarters.
Private Trust Company's Supernus Pharmaceuticals position peaked at $12K in Q3 2022.
333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Private Trust Company's 13F filing for Q4 2025, filed 26 Jan 2026.